Oral pollovaccine: Will it help eradicate polio or cause the next epidemic?

Israel Medical Association Journal

Volumn 8, Issue 5, 2006, Pages 312-315

  Shulman, Lester M ^a   Manor, Yosef ^a   Sofer, Danit ^a   Swartz, Tiberio ^a   Mendelson, Ella ^a,b  

^a MINISTRY OF HEALTH   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Combined polio vaccination program; Environmental surveillance; Molecular epidemiology; Polio intestinal immunity; Vaccine derived poliovirus; Vaccine induced immunity

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; CHILD; CONTROLLED STUDY; DRUG DOSE REGIMEN; ENTEROVIRUS; EPIDEMIC; ERADICATION THERAPY; FECES ANALYSIS; HEALTH PROGRAM; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; ISRAEL; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; POPULATION RESEARCH; SEWAGE; STRAIN IDENTIFICATION; VIRAL GENETICS; VIRUS CHARACTERIZATION; VIRUS EXCRETION; VIRUS ISOLATION; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS TYPING; VIRUS VIRULENCE; CLASSIFICATION; GENETIC RECOMBINATION; GENETIC VARIABILITY; GENETICS; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; PRESCHOOL CHILD; VIROLOGY;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; ENTEROVIRUS; HUMANS; INFANT; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RECOMBINATION, GENETIC; SEWAGE; VARIATION (GENETICS);

EID: 33744499691     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Swartz TA, Handsher R, Manor Y, et al. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Vaccine 1998;16:2090-5.
2. Shulman LM, Handsher R, Yang CF, et al. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J Clin Microbiol 2000;38:945-52.
3. Manor Y, Handsher R, Halmut T, et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J Clin Microbiol 1999;37:1670-5.
4. Shulman LM, Manor Y, Handsher R, et al. Molecular analysis of wild type 1 poliovirus isolated from patients and sewage samples collected in Israel, Gaza, and the West Bank reveals at least three independent introductions of the virus into this region. W54-6. The Xth International Congress of Virology, Jerusalem, Israel, Abstracts 1996:79.
5. Manor Y, Handsher R, Halmut T, et al. A double-selective tissue culture system for isolation of wild-type poliovirus from sewage applied in a long-term environmental surveillance. Appl Environ Microbiol 1999;65:1794-7.
6. Shulman LM, Manor Y, Alfandari J, et al. Rapid evolution by recombination of OPV strains in immunized children in an urban Bedouin community. Program and Abstracts of the Annual Meeting of the Israel Society of Microbiology, Haifa, 9-10 February 2004.
7. Shulman LM, Manor Y, Handsher R, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 2000;38:3729-34.
8. Mendelson E, Shulman LM, Manor Y, et al. Highly evolved, Sabin 2 derived poliovirus strains isolated from sewage in Israel: antigenic and molecular characterization. In: European Virology 2000, Glasgow. J Clin Virol 2002;18(1-3):283.
9. Kinnunen L, Huovilainen A, Poyry T, Hovi T. Rapid molecular evolution of wild type 3 poliovirus during infection in individual hosts. J Gen Virol 1990;71 (Pt 2):317-24.
10. Domingo E, Martinez-Salas E, Sobrino F, et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance - a review. Gene 1985;40:1-8.
11. Agol VI. Recombination and other genomic rearrangements in Picornaviruses. Semin Virol 1997;8:77-84.
12. Wimmer E, Hellen CU, Cao X. Genetics of poliovirus. Annu Rev Genet 1993;27:353-436.
13. McGoldrick A, Macadam AJ, Dunn G, et al. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 1995;69:7601-5.
14. Kilpatrick DR, Ching K, Iber J, et al. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J Clin Microbiol 2004;42:4313-15.
15. Grotto I, Handsher R, Gdalevich M, et al. Decline in immunity to polio among young adults. Vaccine 2001;19:4162-6.
16. Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull WHO 2004;82:16-23.
17. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002;296:356-9.
18. Calderon-Margalit R, Sofer D, Gefen D, et al. Immune status to poliovirus among immigrant workers in Israel. Prev Med 2005; 40:685-9.
19. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 1997;175(Suppl 1):S165-72.
20. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
21. Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull WHO 2004;82:3-8.
22. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587-635.
23. Global Polio Eradication Initiative, strategic plan 2004-2008. Wkly Epidemiol Rec 2004;79:55-7.
24. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004;363:1509-13.